Because of its versatile multikinase properties, entrectinib is approved both for the treatment of advanced or metastatic NTRK fusion-positive tumors in adult and pediatric patients with disease progression following treatment or without satisfactory alternative therapy and for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) [49,50]. Here, ROS1 is linked to non-small cell lung carcinoma.